Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2947-2951

  Dollner, Ralph ^a   Dietz, Andreas ^a   Kopun, Marijana ^b   Helbig, Matthias ^c   Wallner, Frank ^c   Granzow, Christof ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemosensitivity; Glufosfamide; Head and neck carcinoma; HNSCC

Indexed keywords

ALKYLATING AGENT; BETA GLUCOSE; CISPLATIN; GLUCOSE; GLUCOSE TRANSPORTER; GLUFOSFAMIDE; ISOPHOSPHORAMIDE MUSTARD; NEW DRUG; UNCLASSIFIED DRUG;

ARTICLE; BIOEQUIVALENCE; CANCER CHEMOTHERAPY; CELL ASSAY; CLINICAL ARTICLE; COLONY FORMATION; COLONY FORMATION ASSAY; DRUG POTENCY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; EX VIVO STUDY; GENE; GLUCOSE TRANSPORT; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; SAAT1 GENE; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PHOSPHORAMIDE MUSTARDS; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS;

EID: 6444227432     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Pohl J, Bertram B, Hilgard P, Nowrousian MR, Stuben J and Wiessler M: D-19575 - a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother Pharmacol 35: 364-370, 1995.
2. Veyhl M, Wagner K, Volk C, Gorboulev V, Baumgarten K, Weber W-M, Schper M, Bertram B, Wiessler M and Koepsell H: Transport of the new chemotherapeutic agent β-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc Natl Acad Sci 95: 2914-2919, 1998.
3. Smith TA: Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci 56: 285-292, 1999.
4. Seker H, Bertram B, Bürkle A, Kaina B, Pohl J, Koepsell H and Wiessler M: Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. Brit J Cancer 82: 629-634, 2000.
5. Helmke BM, Reisser C, Idzkoe M, Dyckhoff G and Herold-Mende C: Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. Oral Oncol 40: 28-35, 2004.
6. Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebach G, Siamopoulos K, Tzamakou E, Ramou D, Wolf L, Walker R and Hanauske A: Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol 18: 3535-3540, 2000.
7. Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Raoul JL, Hess D, Selvais R, Lacombe D, Bachmann P and Fumoleau P: Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer 39: 2334-2340, 2003.
8. Styczynski J, Wysocki M, Kurylak A, Juraszewska E, Malinowska I, Stanczak E, Ploszynska A, Stefaniak J, Matzur B, Szczepanski T and Ras M: In vitro activity of glufosfamide in childhood acute leukemia. Anticancer Res 22: 247-250, 2002.
9. Dietz A, Rudat V, Staar S, Schröder U and Eckel H: Neue Ergebnisse der multimodalen Therapie von Kopf-Hals-Tumoren. Atemw-Lungenkrkh 27: 285-296, 2001.
10. Airoldi M, Cortesina G, Giordano C, Pedani F and Bumma C: Ifosfamide in the treatment of head and neck cancer. Oncology 65: 37-43, 2003.
11. Catimel G: Head and neck cancer: guidelines for chemotherapy. Drugs 57: 73-88, 1996.
12. Dollner R, Granzow C, Helmke B, Ruess A, Schad A and Dietz A: The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24: 325-332, 2004.
13. Stuben J, Port R, Bertram B, Bollow U, Hull WE, Schapper M, Pohl J and Wiessler M: Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat. Cancer Chemother Pharmacol 38: 355-365, 1996.
14. Dollner R, Kopun M, Dietz A, Wiessler M and Granzow C: Chemoreactivity profiling of HNSCC: equipotentiality of platinum compounds and glufosfamide, a novel alkylating agent. Proc Am Assn Cancer Res 43: 926, 2002.
15. Desoize B, Berthoit G, Manot L, Coninx P and Dumont P: Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur J Cancer 32A: 1734-1738, 1996.
16. Niculescu-Duvaz I: Glufosfamide (Baxter Oncology). Curr Opin Investig Drugs 3: 1527-1532, 2002.
17. van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich C, de Jonge MJ, Brandes A, Frenay M, Carpentier AF, Chollet P, Oliveira J, Baron B, Lacombe D, Schuessler M and Fumoleau P: European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 14: 1732-1734, 2003.
18. Giaccone G, Smit EF, De Jonge M, Dansin E, Briasoulis E, Ardizzoni A, Douillard JY, Spaeth D, Lacombe D, Baron B, Bachmann P and Fumoleau P: Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur J Cancer 40: 667-672, 2004.
19. Yokes EE, Weichselbaum RR, Lippman S and Hong WK: Head and neck cancer. New Engl J Med 328: 184-194, 1993.
20. Hartmann JT and Lipp HP: Toxicity of platinum compounds. Expert Opin Pharmacother 4: 889-901, 2003.